ET has an estimated incidence of 1 to 1.25 cases per million in adults, but it is even rarer in children, with an estimated incidence of 0.09 cases per million. ET is a genetically heterogeneous disease. Mutations in JAK2 have been reported in adults with BCR-ABL–negative MPNs, including ET, PV, and idiopathic myelofibrosis (IM). It has been proposed that ET consists of several subtypes, with some children and adults having monoclonal disease but others having polyclonal disease. Further investigation into the mutational status of JAK2 V617F also demonstrates mutation-positive (roughly 55%) and mutation-negative patients. Another cause of ET was recently demonstrated to be mutations in CALR (calreticulin). Studies suggest that a similar proportion of children with sporadic ET dis play polycythemia rubra vera-1 (PRV-1) RNA overexpression, JAK2 V617F mutations, and monoclonal disease, as compared to adults with sporadic ET. Rare cases of familial ET have been shown to be caused by dominant activating mutations in both c-MPL237 and in JAK2.
Patients with ET have thrombocythemia with an increased number of megakaryocytes in the BM. Platelet clumps on peripheral blood smears are common. Some patients have a concomitant increase in the number of peripheral blood granulocytes. The differential diagnosis includes familial ET, other forms of MPS, and increased platelets as a reactive process.
Although the clinical course can be uncomplicated, patients can develop thromboembolic complications, including deep venous thrombosis, and arterial thrombosis such as transient cerebral ischemia and peripheral vascular ischemia. The clinical course for children is typically less aggressive than in adults, with fewer thrombotic episodes. Adult patients have a median survival of at least 10 years, with most deaths caused by thrombosis. Progression to AML has been reported in adult patients, usually those with a prior exposure to chemotherapy agents.
Asymptomatic children do not require treatment. There is no clear association with platelet count and thrombotic events. As such, there is not a clear role for treatment with aspirin, which can increase the risk of paradoxical bleeding episodes. Risk factors for thrombosis include leukocytosis and the presence of a JAK2 V617F mutation. A number of treatment approaches aimed at controlling thrombocytosis have been attempted for symptomatic patients, including hydroxyurea, IFN-α, and anagrelide.2 The JAK inhibitor ruxolitinib may benefit some patients with ET, especially those with JAK2 V617F mutations, although pediatric-specific data with this agent are lacking. The only potentially curative therapy for ET is allogeneic HCT. Because ET is primarily a disease of older individuals, the data on its efficacy is mainly limited to adult patients with ET that had transformed to myelofibrosis or AML. However, younger patients, and those with matched related donors, did especially well, suggesting that allogeneic transplant should be considered in the rare pediatric patient with symptomatic ET.